spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  NNRTI 

 HSMN NewsFeed - 3 May 2013
Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of SUSTIVA(R) (efavirenz) in HIV-1 Infected Pediatric Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Apr 2010
Ardea Biosciences, Inc. Announces Appointment of Stephen R. Davis as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2010
Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2009
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 15 Sep 2009
European Union Commission Approves Expanded Use of ISENTRESS(R) (raltegravir), from MSD, in Adult Patients with HIV-1 Infection
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 16 Apr 2009
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 11 Feb 2009
PREZISTA(R) Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2009
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Biopharmaceuticals Licensing HIV/AIDS
 HSMN NewsFeed - 5 Feb 2009
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2008
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 29 Aug 2008
INTELENCE(TM) (Etravirine) Receives Marketing Authorisation in the European Union for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 5 Aug 2008
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti-HIV Medicines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2008
Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 21 Jan 2008
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 19 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Dec 2007
Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 21 Dec 2007
ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 28 Nov 2007
Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 15 Nov 2007
Significant Changes in Store for Growing HIV Market
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 15 Oct 2007
UPDATE: FDA Approves ISENTRESS(TM) (raltegravir) Tablets, First-in-Class Oral HIV-1 Integrase Inhibitor
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 28 Sep 2007
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2007
Paramount BioSciences Appoints Business Development Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2007
FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 18 Sep 2007
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Sep 2007
ISENTRESS(TM) (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 17 Sep 2007
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 26 Jul 2007
Ardea Biosciences, Inc. Announces Appointment of Patrick M. O'Connor as Senior Vice President of Research and Preclinical Development and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Jul 2007
TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 16 Feb 2007
Merck & Co., Inc. (1) To Distribute ATRIPLA(TM) in Developing Countries
Biopharmacetuicals HIV/AIDS
 HSMN NewsFeed - 16 Feb 2007
Anti-HIV Medication PREZISTA(TM) Receives Conditional Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 22 Dec 2006
Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change
Biopharmaceuticals Acquisitions Personnel
 HSMN NewsFeed - 9 Oct 2006
Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 2 Oct 2006
Viral Suppression in Triple-Class Drug Resistant Patients Maintained after 24 Weeks of Treatment with MK-0518, an Investigational HIV Integrase Inhibitor, Plus Optimized Background Therapy (OBT)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Virologic and Drug Resistance Results from Protease Inhibitor Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Sep 2006
Tibotec Therapeutics Announces Initiation of the Largest U.S. Clinical Study Examining HIV Treatment in Treatment-Experienced Adult Women
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 13 Sep 2006
Bristol-Myers Squibb Company and Medivir AB Announce Worldwide Collaboration to Develop and Commercialize MIV-170 for the Treatment of HIV-1 Infection in Adults
Biopharmaceuticals HIV/AIDS Licensing
 HSMN NewsFeed - 12 Jul 2006
U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection
Biopharmaceuticals FDA HIV/AIDS
Return to NewsFeed  

 Additional items found! 36

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 36 additional stories matching:
NNRTI
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.